Sign up to save your podcasts
Or
Share Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
Adding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.
View all episodes
By TheBrief.HealthAdding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.